Titan Biotech (BSE: 524717) has compounded its Earnings Per Share at 28.6% CAGR over 10 years — from ₹0.42 in FY2015 to ₹5.21 in FY2025. This deep-dive case study reveals what EPS growth analysis tells us about business quality and how to use it for intrinsic value estimation.